JSKN-021

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameJSKN-021
Drug Alias NameJSKN-021
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[5] 
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I +[4] 
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAlphamab Oncology
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Alphamab Biopharmaceuticals Co Ltd
Inactive CompaniesAlphamab Oncology
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A